Massachusetts Eye and Ear Infirmary
masseyeandear.orgTotal trials
98
Active
28
Phase 3
6
Total enrollment
11,524
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 17 of 17 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Triamcinolone Acetonide 40mg/mL | — | — | — | — | — | 1 | |
| Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin | — | — | — | — | — | 1 | |
| Prednisolone 1% | — | — | — | — | — | 1 | |
| Atropine 1% | — | — | — | — | — | 1 | |
| Netarsudil Ophthalmic | — | — | — | — | 2 | ||
| Doxycycline Injection [Doxy] | — | — | — | — | — | 1 | |
| Aspirin | — | — | — | — | — | 1 | |
| Lactobacillus plantarum 299v | — | — | — | — | — | 1 | |
| N-acetyl cysteine (NAC) 10% solution | — | — | — | — | — | 1 | |
| N-acetyl cysteine (NAC) 20% solution | — | — | — | — | — | 1 | |
| Visine Dry Eye Relief eye drops | — | — | — | — | — | 1 | |
| LENVATINIB | — | — | — | — | — | 1 | |
| Atorvastatin 80mg | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | 2 | ||
| Topotecan | — | — | — | — | — | 1 | |
| Adalimumab | — | — | — | — | — | 1 | |
| Laryngeal sensory block with topical bupivacaine | — | — | — | — | — | 1 |
Next readouts
- 2025-05-27
- 2026-04-29
- 2026-07-25
- 2026-08
- 2026-09
- 2026-09-01
- 2026-12-01
- 2027-03-01
- 2027-04-01
- 2027-06-01
Top conditions
- Glaucoma7
- Spasmodic Dysphonia4
- Vestibular Schwannoma4
- Vestibular Disorder4
- Rhegmatogenous Retinal Detachment3
- Neurofibromatosis Type 23
- Laryngeal Dystonia3
- Tremor3
Frequently asked questions about Massachusetts Eye and Ear Infirmary
- How many clinical trials does Massachusetts Eye and Ear Infirmary have on ClinicalTrials.gov?
- Massachusetts Eye and Ear Infirmary is listed as the lead sponsor on 98 clinical trials in ClinicalTrials.gov, 28 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Massachusetts Eye and Ear Infirmary's trials are in Phase 3?
- 6 of Massachusetts Eye and Ear Infirmary's trials are in Phase 3, spread across 17 active drug programs.
- What therapeutic areas does Massachusetts Eye and Ear Infirmary focus on?
- Massachusetts Eye and Ear Infirmary's most-studied conditions on ClinicalTrials.gov are Glaucoma, Spasmodic Dysphonia, Vestibular Schwannoma, Vestibular Disorder, Rhegmatogenous Retinal Detachment.
- When are Massachusetts Eye and Ear Infirmary's next clinical trial readouts?
- Massachusetts Eye and Ear Infirmary has 10 upcoming primary-completion readouts tracked here; the soonest is “Lenvatinib in Locally Advanced Invasive Thyroid Cancer”, expected around 2025-05-27.